ARTIS Ventures’ Post

Curious about our ETCer bispecific TCR therapeutics? Each one is made of a high affinity target-binding TCR linked to an anti-CD3 T cell effector via a silenced Fc domain. We use our EMLy™machine learning platform, powered by generative AI and structural modelling, to discover and engineer TCRs to picomolar affinity. We then then use these TCRs to build soluble bispecific ETCers for treating cancer and more. Check out our recent article to learn more about the power of TCR therapeutics and our approach: https://lnkd.in/eFPZQ22D #TCR #biotech #oncology #immunotherapy #TCREuphoria #GenerativeAI #techbio

CTC diagnostics involves the detection and analysis of cancer cells that have broken away from the primary tumor and are circulating in the bloodstream. These cells provide invaluable insights into the progression of cancer, enabling oncologists to monitor the disease in real-time, tailor treatments to individual patients, and potentially improve outcomes.   Top Global Circulating Tumor Cell Diagnostics Industry Players: QIAGEN Bio-Techne Precision For Medicine BioCep Greiner Bio-One International Ikonisys Miltenyi Biotec BioFluidica, Inc. Biolidics Limited (Formerly known as Clearbridge BioMedics) Epic Sciences Rarecells ScreenCell Menarini Silicon Biosystems Vitatex Inc   Read More @ https://lnkd.in/dz9zMhuj   #ctcdiagnostics #liquidbiopsy #precisionmedicine #cancerdiagnostics #oncology #biotechnology #medtech #ctc #marketgrowth#liquidbiopsy #personalizedmedicinerevolution #healthcare #investinginhealthcare #ctcdrugdevelopment #earlycancerdetection #residualdisease #cancertreatment #startup #metastatinsight

🚨BREAKING NEWS!🚨   With the FDA's recent fast track designation for Carisma Therapeutics' CT-0525, a revolutionary CAR-Monocyte cellular therapy, the potential for macrophage-directed therapies to address unmet needs in treating HER2-overexpressing solid tumors has never been more evident.   And guess what? 𝗖𝗮𝗿𝗶𝘀𝗺𝗮 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 is on the speaker faculty for the 6th Macrophage-Directed Therapies Summit!🔥   This is a timely opportunity to shake hands with Bindu Varghese (from 𝗖𝗮𝗿𝗶𝘀𝗺𝗮 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀), who will be presenting on "Engineering Myeloid Cells for Cancer - Ex Vivo & In Vivo Approaches."   📖𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗴𝗲𝗻𝗱𝗮 - https://ter.li/9vo845    🎟️𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗯𝘆 𝗺𝗶𝗱𝗻𝗶𝗴𝗵𝘁 𝘁𝗼 𝘀𝗲𝗰𝘂𝗿𝗲 $𝟵𝟬𝟬 𝗶𝗻 𝘀𝗮𝘃𝗶𝗻𝗴𝘀 - https://ter.li/t2kq70   Now's your chance to join this exclusive forum, dedicated to unraveling complex macrophage biology, accelerating novel target discovery, and driving clinical proof of concept to unleash the blockbuster potential of macrophage therapeutics.   Plus, seize our 𝗴𝗿𝗼𝘂𝗽 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁𝘀 𝗼𝗳 𝘂𝗽 𝘁𝗼 𝟮𝟬% 𝗼𝗳𝗳! Don't let this transformative event pass you by, especially with the space looking incredibly promising! #𝗠𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲𝗗𝗶𝗿𝗲𝗰𝘁𝗲𝗱𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀𝗦𝘂𝗺𝗺𝗶𝘁

⏰ TOMORROW: Don’t miss your opportunity to engage live with the principal curator behind COSMIC Actionability! Join us tomorrow, March 7 at 11 a.m. EST / 4 p.m. GMT for an exclusive interactive webinar featuring Dr. Steve Jupe, COSMIC Actionability's principal curator and Dr. Kyle Nilson, field software trainer at QIAGEN Digital Insights. In this webinar, you’ll explore a series of use cases demonstrating how #cancer and #biopharma labs like yours can harness COSMIC (Catalogue of Somatic Mutations in Cancer) to: ➡️ Evaluate genomic loci using COSMIC’s comprehensive coding and non-coding variant annotations. ➡️ Integrate variants with curated findings and summaries of mutational impact and clinical actionability. ➡️ Use mutational signatures for potential clinical diagnosis and drug development applications.   Hurry – there’s still time! Register now 👇 Can’t make it at this time? Don’t worry. Register now and we’ll send you the on-demand recording as soon as its available. #drugdevelopment #precisiononcology

One of the key topic areas at #WorldCBandCDx includes CDx in ADCs. #Geneexpression will play a critical role in the development of ADC therapies, the next generation of immunotherapies that hold huge potential for cancer patients. Understanding #transcriptomics data to reveal tumor heterogeneity, immune responses and biomarkers discovery are diverse areas where latest #cfRNA NGS technologies can be utilized to accelerate ADC drug development. Sysmex Inostics’ broad portfolio of comprehensive cfRNA plus cfDNA panels can provide unique solutions to your liquid biopsy needs for ADCs. Come speak with our experts to learn how we can expedite your ADC clinical trials! https://hubs.la/Q02L8G6-0 #cellfreeDNA #ADCs #ADCclinicaltrial

🚀 Big Pharma meets AI: AstraZeneca has inked a groundbreaking deal, up to $247M, with Absci Corp. to leverage cutting-edge AI for protein analysis in the hunt for transformative cancer treatments. This collaboration exemplifies the fusion of biotech and AI, potentially accelerating the path to innovative therapies. Stay tuned for how this partnership might change the game in the fight against cancer. 🧬💡 #AstraZeneca #Absci #ArtificialIntelligence #ProteinAnalysis #CancerTherapy #Biotech #Innovation #HealthTech #BigData #MachineLearning #AIinHealthcare #PharmaTech #FutureOfMedicine #TechCollaboration

𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐂𝐮𝐫𝐫𝐞𝐧𝐭 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐚𝐧𝐝 𝐅𝐮𝐭𝐮𝐫𝐞 𝐏𝐫𝐨𝐬𝐩𝐞𝐜𝐭𝐬 🌐𝑫𝒐𝒘𝒏𝒍𝒐𝒂𝒅 𝑷𝑫𝑭 𝑩𝒓𝒐𝒄𝒉𝒖𝒓𝒆: bit.ly/3WOVxRK The report "#cancerdiagnostics Market by Product (Consumables (Anitibodies, Probes), Instruments (Pathology Instruments, Imaging Instruments, Biopsy), Technology (IVD Testing), Application (Breast Cancer, Lung Cancer), End User (Hospitals) - Global Forecasts to 2026" 𝐓𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐜𝐚𝐧𝐜𝐞𝐫 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐬𝐢𝐳𝐞 𝐢𝐬 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐔𝐒𝐃 𝟐𝟔.𝟔 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟐𝟔 𝐟𝐫𝐨𝐦 𝐔𝐒𝐃 𝟏𝟕.𝟐 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟏, 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟏𝟏.𝟓%. The growth in this market is attributed to the increasing incidence of cancer and increasing number of private diagnostic laboratories. Danaher Corporation, Becton, Dickinson and Company, Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd, QIAGEN, FUJIFILM Corporation, Thermo Fisher Scientific, etc. #cancerdiagnostics #cancerdetection #oncologytesting #precisionmedicine #earlydetection #tumordiagnosis #medicalimaging #biomarkertesting #liquidbiopsy #personalizedmedicine #genetictesting #cancerscreening #pathologyservices #moleculardiagnostics 

⏰ TOMORROW: Don’t miss your opportunity to engage live with the principal curator behind COSMIC Actionability!   Join us tomorrow, March 7 at 11 a.m. EST / 4 p.m. GMT for an exclusive interactive webinar featuring Dr. Steve Jupe, COSMIC Actionability's principal curator and Dr. Kyle Nilson, field software trainer at QIAGEN Digital Insights. In this webinar, you’ll explore a series of use cases demonstrating how #cancer and #biopharma labs like yours can harness @Catalogue Of Somatic Mutations In Cancer (COSMIC), to:   ● Evaluate genomic loci using COSMIC’s comprehensive coding and non-coding variant annotations. ● Integrate variants with curated findings and summaries of mutational impact and clinical actionability. ● Use mutational signatures for potential clinical diagnosis and drug development applications.   Hurry—there’s still time, register now!   Can’t make it at this time? Don’t worry. Register now and we’ll send you the on-demand recording as soon as its available.   #drugdevelopment #precisiononcology https://lnkd.in/dfrPfgRx

This is a great article from Pierre Arsène, he is on the money that the future of healthcare is even more orientated towards prevention over cure and that requires significant investment in diagnostics. Looking at Liver Disease alone is a signficant area of cost rivalling other areas considered way more critical. Cirrhosis costs the U.S. healthcare system as much as heart failure. Healthcare reimbursement is shifting from fee-for-service to fee-for-value and EVs should enable that EV's (#ExtracellularVesicles) offer this potential benefit at scale and with accessibility. and there are a lot of papers in the management of chronic diseases that discuss the need to do things better to avoid litigation and other costs associated with poor care which derives from poor diagnostic management. Liability is one such area of cost:- EV's should be that game changing model and Mursla Bio are best positioned to exploit that.

One more building block towards completing Precision Cancer Solutions. How Mirxes grew from miRNA as core product to a solution platform in Precision Cancer. Its not for the faint hearted. Moving to our next building block… Mirxes #biotechnology #precisionmedicine #biotech #precisioncancer #precisionhealth #personalisedtreatment